INCIDENCE, PREDICTORS AND IMPACT OF MAJOR BLEEDING IN PATIENTS UNDERGOING TRANSFEMORAL TRANSCATHETER AORTIC VALVE REPLACEMENT WITH BIVALIRUDIN OR UNFRACTIONATED HEPARIN: FROM THE EFFECT OF BIVALIRUDIN ON AORTIC VALVE INTERVENTION OUTCOMES (BRAVO) TRIAL